Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia

Phase 3 Terminated 146 enrolled Servier ADIR, a Servier Group company · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to demonstrate the superiority of atorvastatin/perindopril fixed dose combination (FDC) S05167 as compared to atorvastatin reference drug alone or perindopril drug alone on systolic blood pressure decrease and LDL cholesterol decrease respectively in patients presenting with hypertension and dyslipidemia after 8 weeks of treatment.

Timeline

Start: 2021-09-09
Primary completion: 2022-04-08
Completion: 2022-04-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atorvastatin	Small molecule	40 mg	—
Subject	Perindopril	Small molecule	10 mg	—

Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia

Summary

Timeline

Drugs

Indications